Literature DB >> 10369451

Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

S Murata1, T Taniguchi, I Muramatsu.   

Abstract

Pharmacological profiles of tritiated KMD-3213, a new antagonist of alpha1-adrenoceptor (AR), were examined in recombinant and native alpha1-AR, and compared with those of prazosin (PZ) and tamsulosin (YM-617). In saturation experiments, [3H]-KMD (10-2000 pM) showed high affinity for alpha1a-AR (pK(D) = 10.5). However, no significant binding to alpha1b-AR and insufficient/unsaturated binding to alpha1d-AR were observed at concentrations up to 2000 pM. In contrast, [3H]-PZ and [3H]-YM bound to all subtypes with high affinity (pK(D)>9). In competition experiments, KMD-3213 also had higher affinity for alpha1a-AR than for other two subtypes; pKi = 10.4, 8.1 and 8.6 for alpha1a-, alpha1b- and alpha1d-AR, respectively. [3H]-KMD also bound to the native alpha1A-AR (rat submaxillary gland) with high affinity, but not to alpha1B-AR (rat liver). In rat kidney which expresses alpha1A- and alpha1B-AR, [3H]-KMD and [3H]-PZ bound to a single high-affinity site (pK(D) = 10.8 and 10.1, respectively) with distinct amount of binding sites (Bmax = 159 and 267 fmol mg(-1) protein, respectively). [3H]-PZ binding sites consisted of low- and high-affinity sites for KMD-3213 (pKi = 7.6 and 10.7, respectively), for WB4101 (pK = 8.1 and 10.0) and for YM-617 (pKi = 8.7 and 10.8). The proportion of the high affinity site was approximately 60% in these drugs which was compatible to the ratio between Bmax of [3H]-KMD and [3H]-PZ. [3H]-KMD binding sites consisted of a single site for these drugs with affinities which were similar to those of the high affinity sites in [3H]-PZ binding. In functional experiments, KMD-3213 antagonized the contractile responses to NS-49 or noradrenaline (NA) with higher affinity in functional alpha1A- (rat caudal artery, pA2= 10.0 against NS-49) and alpha1L-AR (dog mesenteric artery, pA2 = 9.9 against NA) than in alpha1B- (dog carotid artery, pA2 = 7.7 against NA) and alpha1D-AR (rat thoracic aorta, pA2 = 8.3 against NA). These results confirm the alpha1A-AR selectivity and high affinity of KMD-3213, and indicate that [3H]-KMD can label selectively alpha1A-AR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369451      PMCID: PMC1565976          DOI: 10.1038/sj.bjp.0702489

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat.

Authors:  W G Lachnit; A M Tran; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

2.  Characterization of specific binding of [125I]L-762,459, a selective alpha1A-adrenoceptor radioligand to rat and human tissues.

Authors:  S S O'Malley; T B Chen; B E Francis; R E Gibson; H D Burns; J DiSalvo; M L Bayne; J M Wetzel; D Nagarathnam; M Marzabadi; C Gluchowski; R S Chang
Journal:  Eur J Pharmacol       Date:  1998-05-08       Impact factor: 4.432

3.  Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms.

Authors:  D J Chang; T K Chang; S S Yamanishi; F H Salazar; A H Kosaka; R Khare; S Bhakta; J R Jasper; I S Shieh; J D Lesnick; A P Ford; D V Daniels; R M Eglen; D E Clarke; C Bach; H W Chan
Journal:  FEBS Lett       Date:  1998-01-30       Impact factor: 4.124

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  KMD-3213, a novel alpha1A-adrenoceptor antagonist, potently inhibits the functional alpha1-adrenoceptor in human prostate.

Authors:  N Moriyama; K Akiyama; S Murata; J Taniguchi; N Ishida; S Yamazaki; K Kawabe
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

6.  Is alpha1D-adrenoceptor protein detectable in rat tissues?

Authors:  M Yang; F Verfürth; R Büscher; M C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-04       Impact factor: 3.000

7.  Alpha1L-adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man.

Authors:  M S Kava; D R Blue; R L Vimont; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

8.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

Review 10.  Evidence for more than one type of post-junctional alpha-adrenoceptor.

Authors:  J C McGrath
Journal:  Biochem Pharmacol       Date:  1982-02-15       Impact factor: 5.858

View more
  17 in total

1.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Authors:  Chihiro Hosoda; Akito Tanoue; Mari Shibano; Yoshio Tanaka; Masami Hiroyama; Taka-aki Koshimizu; Susanna Cotecchia; Tadaichi Kitamura; Gozoh Tsujimoto; Katsuo Koike
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

6.  Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

Authors:  I Muramatsu; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; M C Rodrigo; B E Myagmar; P C Simpson
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

Review 7.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

8.  Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Abu Syed Md Anisuzzaman; Hidenori Umada; Ryoji Hayashi; Mie Kainoh; Takayoshi Masuoka; Matomo Nishio; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 9.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

10.  Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate.

Authors:  T-H Su; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; J-T Cheng; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.